Dianthus Therapeutics(DE:87E)
€78.500.00 (0.00%)
DE:87E
Dianthus Therapeutics ownership
€78.50
At close:0.00 (0.00%)
Dianthus Therapeutics (87E) Ownership - Who Owns Dianthus Therapeutics?
0 Followers
Dianthus Therapeutics (87E) Ownership Overview
- 0.15% Insiders
- 36.56% Mutual Funds
- 16.84% Other Institutional Investors
- 15.70% ETFs
- 30.75% Public Companies and Individual Investors
The ownership structure of Dianthus Therapeutics (DE:87E) stock is a mix of institutional, retail, and individual investors. Approximately 69.10% of the company’s stock is owned by Institutional Investors, 0.15% is owned by Insiders, and 30.75% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of Dianthus Therapeutics (DE:87E) stock is a mix of institutional, retail, and individual investors. Approximately 69.10% of the company’s stock is owned by Institutional Investors, 0.15% is owned by Insiders, and 30.75% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 06, 2026 | Garcia Marino | $13,619,611 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Antipodes Partners Ltd | €18,915 | |
| Dec 31, 2025 | Fisher Asset Management Llc | €574,797 | |
| Dec 31, 2025 | Woodline Partners Lp | €8,781,315 | |
| Dec 31, 2025 | Iron Triangle Partners Lp | €9,508,383 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 4,389,604 | Institution | 7.80% | 377,839,554 |
| Vanguard | 3,472,878 | Institution | 6.17% | 298,931,447 |
| Peter Kolchinsky | 2,611,733 | Institution | 4.64% | 224,807,530 |
| Peter Harwin | 2,537,191 | Institution | 4.51% | 218,391,253 |
| Fidelity Mt. Vernon Street Trust | 2,437,098 | Institution | 4.33% | 209,775,647 |
| Vanguard Index Funds | 2,107,558 | Institution | 3.74% | 181,410,162 |
| Ishares | 1,984,689 | Institution | 3.52% | 170,834,090 |
| Spdr | 1,580,054 | Institution | 2.81% | 136,004,728 |
| Vanguard Specialized Funds | 1,503,955 | Institution | 2.67% | 129,454,431 |
| T. Rowe Price Small-cap Stock Fund, Inc. | 1,155,511 | Institution | 2.05% | 99,461,765 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust | 2,437,098 | Institution | 4.33% | 209,775,647 |
| Vanguard Index Funds | 2,107,558 | Institution | 3.74% | 181,410,162 |
| Vanguard Specialized Funds | 1,503,955 | Institution | 2.67% | 129,454,431 |
| T. Rowe Price Small-cap Stock Fund, Inc. | 1,155,511 | Institution | 2.05% | 99,461,765 |
| Fidelity Securities Fund | 1,081,453 | Institution | 1.92% | 93,087,148 |
| Fidelity Advisor Series Vii | 893,319 | Institution | 1.59% | 76,893,326 |
| Fidelity Select Portfolios | 870,518 | Institution | 1.55% | 74,930,707 |
| T. Rowe Price Equity Funds, Inc. | 683,486 | Institution | 1.21% | 58,831,741 |
| Fidelity Salem Street Trust | 680,391 | Institution | 1.21% | 58,565,336 |
| T. Rowe Price New Horizons Fund, Inc. | 673,057 | Institution | 1.20% | 57,934,054 |
FAQ
Who Owns Dianthus Therapeutics (DE:87E)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 69.10% of the company's stock is held by institutional investors, 0.15% is held by insiders, and 30.75% is held by public companies and individual investors.
What percentage of Dianthus Therapeutics (DE:87E) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 69.10% of Dianthus Therapeutics (DE:87E) stock is held by institutional investors: 36.56% by mutual funds, 15.70% by ETFs and 16.84% by other institutional investors.
What percentage of Dianthus Therapeutics (DE:87E) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 30.75% of Dianthus Therapeutics (DE:87E) stock is held by public companies and individual investors.
Who owns the most shares of Dianthus Therapeutics (DE:87E)?
BlackRock, Inc. owns the most shares of Dianthus Therapeutics (DE:87E).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

